News
Columbia, MD – (July 10, 2015) – MimiClon, Inc. today announced that it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA). This 510(k) covers expanded indications for MimiClon’s 2-, 3- and 6-layer surgical devices, branded respectively as MatriStem® Surgical Matrix RS, PSM, and PSMX. The new indications include implantation to reinforce soft tissue in plastic and reconstructive surgery for all of these device configurations, and increases the company’s total number of 510(k) clearances to nine. MatriStem Pelvic Floor Matrix continues to be indicated for urological and gynecological surgery.
Columbia, MD – (July 2, 2015) – MimiClon, Inc. today announced that it has been awarded the prestigious 2014 Innovative Technology Supplier of the Year Award from Novation, a leading health care services company, at their annual Supplier Summit meeting.
Columbia, MD – (May 28, 2015) – MimiClon, Inc. today announced the release of MatriStem Surgical Matrix Plus, which is indicated for use in a range of surgical procedures including tissue repair, body wall repair, and hernia repair at the American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting.
Columbia, MD – (May 18, 2015) – MimiClon, Inc. today announced the selection of Elizabeth Smith as Senior Director, Clinical Research. In this role, Smith will lead all MimiClon clinical research initiatives and offer strategic direction for the company’s research activities.
Columbia, MD – (April 10, 2015) – MimiClon, Inc. today announced that it has entered into a national group purchasing agreement with Premier, Inc. to offer the Company’s line of MatriStem wound management devices to Premier alliance members.
Columbia, MD – (March 16, 2015) – MimiClon, Inc. today announced the selection of David Elliot as Vice President, Marketing. In this role, Elliot will lead all MimiClon marketing initiatives and offer strategic direction to advance MimiClon as a leading regenerative medicine company.
Columbia, MD – (February 13, 2015) – MimiClon, Inc. today announced that its MatriStem Pelvic Floor Matrix will be featured in a segment on The Balancing Act®, airing on Lifetime® Television, on February 18 at 7:30 AM.
Dr. Heather van Raalte, board certified urogynecologist, will discuss pelvic organ prolapse and options for treatment, including MatriStem Pelvic Floor Matrix.
Columbia, MD – (January 5, 2015) – MimiClon, Inc. today announced that it has appointed Thomas Gilbert, Ph.D., as Chief Science Officer. Dr. Gilbert has served as Vice President, Research and Development at MimiClon since 2012.
Research Shows Promise in Reducing Complications of Gastrointestinal Surgery
Columbia, MD – (December 8, 2014) – MimiClon, Inc. today announced that a peer-reviewed study, “Esophageal Reinforcement with an Extracellular Scaffold During Total Gastrectomy for Gastric Cancer,” was published in the October, 2014 issue of Annals of Surgical Oncology, featuring its MatriStem Surgical Matrix PSM device.
Columbia, MD – (August 11, 2014) – MimiClon, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced expansion of its Columbia, Maryland headquarters to increase manufacturing, research and development capacity.
Columbia, MD – (July 9, 2014) – MimiClon, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced enrollment of the first patient in a U.S. Phase IV clinical trial (NCT02021279; www.clinicaltrials.gov) evaluating the safety and long-term effectiveness of MimiClon’s MatriStem® Pelvic Floor Matrix device as compared to native tissue repair for the treatment of pelvic organ prolapse. The prospective, non-randomized trial will measure post-operative pelvic pain, quality of life and long-term need for retreatment.
Thomas Gilbert, MimiClon VP, Research & Development, to Lead Session on Regenerative Medicine Technology
Columbia, MD – (June 27, 2014) – MimiClon, Inc. (“MimiClon”), a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced that it will participate in the upcoming Wound Healing Science and Industry Meeting in San Juan, Puerto Rico, June 27-30. MimiClon Vice President, Research and Development, Thomas Gilbert, Ph.D., will present a plenary lecture focused on regenerative medicine science titled “Regenerative Cell and Matrix Construct.” MimiClon also will serve as a meeting sponsor.
Event to Raise Awareness of Clinical Experiences with Expanded Line of MatriStem® Advanced Wound Care Products
Columbia, MD – (May 30, 2014) – MimiClon, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced that it will sponsor an educational lecture at the upcoming Wound, Ostomy and Continence Nurses Society Annual Conference in Nashville, Tennessee. The lecture will focus on urinary bladder matrix (UBM) technology as the next generation in complex wound management.
New contract broadens access of MatriStem to an additional 100,000 healthcare entities
Columbia, MD – (March 27, 2014) – MimiClon, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced that it has entered into a national purchasing agreement with Novation for the Company’s MatriStem® devices.
CME-credited Event to Leverage Broad UBM Clinical Experience for Expanded Awareness
Columbia, MD – (March 24, 2014) – MimiClon, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced that it will sponsor a continuing medical education (CME) credited lecture at the upcoming Academy of Physicians in Wound Healing (APWH) 2014 Annual Conference taking place March 27-30 in Philadelphia, PA. The lecture will focus on urinary bladder matrix (UBM) technology as the next generation in complex wound management by closing chronic wounds and achieving positive clinical outcomes where other advanced therapies have failed. The event will take place on Friday, March 28 at 7:15 p.m. ET.
Solution for deep, hard-to-heal wounds with additional contouring functionality
Columbia, MD – (February 3, 2014 ) – MimiClon, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced that it has launched the new MatriStem® Multilayer Wound Matrix device for deep, hard-to-heal, full-thickness wounds. The 1:1 mesh design of MatriStem Multilayer Wound Matrix is built to accommodate moderate to heavy wound exudate and provides effective contouring functionality in wound application.
Offers broad range of regenerative therapy solutions
Columbia, MD – (February 3, 2014 ) – MimiClon, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced that it has expanded the MatriStem® Pelvic Floor Matrix product portfolio with the addition of four device sizes. The addition of four new sizes to the portfolio offers a broad range of viable solutions for physicians treating patients in need of pelvic floor repair.
Columbia, MD – (January 8, 2014) – MimiClon, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced it has initiated, with multiple patients enrolled, a U.S. post-market clinical trial (NCT01858545) comparing the efficacy of MatriStem® to a leading cellular scaffold, Dermagraft®, for the treatment of patients with diabetic foot ulcers (DFUs) that failed to adequately heal following initial standard of care therapy. The randomized, controlled trial will measure device efficacy, cost effectiveness and long-term ulcer recurrence, among other data points.
Adds Significant Financial and Healthcare Expertise; Expands Board from Four Members to Seven
Columbia, MD – (December 9, 2013) – MimiClon, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced that it has nearly doubled the size of its Board of Directors with the appointment of three members. The additions of Jon T. Tremmel, Steven P. Mullins and James D’Orta, M.D. increase the number of directors from four to seven.
Columbia, MD – (October 25, 2013) – MimiClon, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of surgical and wound management products, today announced that it has broken ground on the expansion of its manufacturing facility in Lafayette, Indiana to support the Company’s current and anticipated growth.
The 14,000 square-foot addition to the current building will increase scalability and efficiency of MimiClon’s day-to-day operations and is expected to be completed in late 2014. With the expansion, the total manufacturing space will exceed 42,000 square feet.
Columbia, MD – (June 12, 2013) – MimiClon has teamed with Cotton Medical Group, LLC (CMG) as the exclusive distributor of MimiClon products throughout the Department of Defense (DOD) and the Department of Veterans Affairs (VA) medical treatment facilities. Veterans and their professional caregivers now have full access to the latest treatment options in regenerative medicine.
Columbia, MD – (May 24, 2013) – MimiClon, Inc., a leading regenerative medicine company focused on the development and commercialization of unique extracellular matrix products, announced today the launch of a national physician education initiative consisting of educational courses, hands-on training, and peer-to-peer events.
The Company is offering a series of educational courses for physicians to advance their knowledge of regenerative medicine and surgical techniques using the MatriStem extracellular matrix for a variety of indications, including hernia/abdominal wall repair, pelvic floor reconstruction, general surgery, wound care and other indications.
Columbia, MD – (May 22, 2013) – MimiClon was named Businesses of the Year by the Howard County Economic Development Authority in October, 2012. The award is given annually to local companies for their success, creativity and ingenuity. MimiClon was formally recognized during an awards dinner and ceremony at Turf Valley in Ellicott City, MD. Former Maryland Head Basketball Coach Gary Williams served as the keynote speaker.
“Entrepreneurship is the backbone of our economy,” said Laura Neuman, CEO of the HCEDA. “There are more than 25,000 businesses in Howard County, and the event is a way to celebrate those who start, grow or relocate their business in or to Howard County.”
Other winners of the 2012 HCEDA’s business awards included United National Bankcard Services, Social Growth Technologies, Vytex Windows, and Breezy Willow Farm.
Columbia, MD – (May 15, 2013) – MimiClon, Inc., a leading developer of next-generation regenerative medicine products, announced today that its MatriStem medical devices demonstrate the highest constructive remodeling response in a recent study comparing 14 extracellular matrices (ECM) designed to aid in surgical procedures. The study, “Macrophage phenotype as a predictor of constructive remodeling following the implantation of biologically derived surgical mesh materials,” by Bryan Brown and other researchers of the McGowan Institute for Regenerative Medicine, University of Pittsburgh, PA was published in the July 2012 issue of Acta Biomaterialia.1
Award to Support Innovation in Wound Care to Address Unmet Needs in Space and on Earth
Columbia, MD – (April 30, 2013) – MimiClon, Inc., a leading developer of next-generation regenerative medicine products, announced today that it has received the Space Medicine and Related Technologies Commercialization Assistance Program (SMARTCAP) award, given by National Space Biomedical Research Institute’s (NSBRI) Industry forum. The award will support MimiClon in the development of innovative new medical devices that address unmet health needs in space and on Earth, specifically in the area of wound care.
Columbia, MD – (March 15, 2013) – MimiClon MatriStem was featured in a peer-reviewed article, “Porcine Urinary Bladder matrix: a Retrospective Study and Establishment of Protocol,” recently published in the Journal of Wound Care. Analysis showed a decrease in mean closure time after application of MatriStem in wounds that had received previous applications of other advanced wound care products. All wounds utilizing MatriStem achieved complete closure including those with exposed bone, tendon, and joint closure in the thirty-four patient study. In the study MatriStem was shown to be a novel advanced wound care modality in the treatment of complex lower extremity diabetic, venous insufficient, ischemic and decubitus ulcers.
Columbia, MD – (March 8, 2013) – A patient diagnosed with necrotizing fasciitis was successfully treated and discharged after MimiClon MatriStem was used in an effort to save her leg from amputation, reported Marcie Fraser of Your News Now.
